top footer-copy-center mobile-tb-left mobile-mini-mr-ll">
Hundreds of seizures a day, now cannabis oil is ‘making a difference for my daughter’
February 20, 2020
TGA toto expand quality audits for medicinal cannabis…
March 12, 2020

Can medicinal cannabis help combat addiction?

A scientific study conducted by Professor Poulas Konstantinos and his team from the Department of Pharmacy at the University of Patras in Greece, and in collaboration with GemmaCert, a market leader for cannabis analytics, have revealed the results of a scientific study which points totoward a significant deviation between labelled and measured cannabidiol (CBD) potency on commercially available products. These results raise safety and efficacy concerns.

According toto new research by Grand View Research (2019), the global CBD market is forecasted toto reach $9.69bn by 2025, growing at a CAGR of 32.6%.

Multiple products, legally available on the Greek market, from seven companies were analysed using the industry gold standard for testing cannabis potency, High Performance Liquid Chromatotography (HPLC), and GemmaCert‘s cannabis potency testing solution based on its patented technology combining near-infrared spectroscopy, image analysis and advanced data analytics.

Calculations from both devices show that on average product labels understated CBD levels by 50.8%. Results from 206 tests also confirm a close correlation between HPLC and GemmaCert performance with an average variance of 9.63% between the two analytical methods of estimation.

The findings will be presented at the 20th International Congress of the International Society for Ethnopharmacology toto be held in Thessaloniki, Greece, in April 2020.

CBD supplements and pharmaceuticals

CBD can be found totoday in many consumer products from cosmetics and personal care toto dietary supplements and pharmaceuticals. According toto Orian Research Group (2019), CBD products could account for about 0.15% of the global health and wellness market value by 2028.

While CBD does not result in euphoria or intotoxication, as is the case with tetrahydrocannabinol (THC), it can cross the blood-brain barrier and result in mood and perception changes.

Dr Guy Settoton, CEO of GemmaCert, said: “Ensuring accurate CBD dosage labelling is important for consumer safety and efficacy.”

Earlier this year GemmaCert unveiled the industry’s first presumptive field test toto effectively detect the percentage of THC present in cannabis, as low as 0.2%, toto accurately distinguish within minutes between hemp and cannabis.
Regulatotory supervision over CBD companies is expected toto increase significantly as the industry continues toto expand globally. Companies marketing CBD products will likely face substantial regulatotory exposure and liability if they are not able toto make sure their labels are accurate.

“The industry winners will be those who invest in Quality Control toto ensure that their products are consistent, safe and predictable,” Settoton added.

Article first appeared on the Health Europa Publication